Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers.

@article{Schwartz2001EffectOR,
  title={Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers.},
  author={Jules I. Schwartz and Marina De Smet and Patrick J. Larson and Ren{\'e} Verbesselt and David L. Ebel and Robert Lins and Simone Lens and Arturo G. Porras and Barry J. Gertz},
  journal={Journal of clinical pharmacology},
  year={2001},
  volume={41 1},
  pages={
          107-12
        }
}
The authors examined the effect of the cyclooxygenase-2 (COX-2) inhibitor, rofecoxib, at steady state on the pharmacokinetics of digoxin following a single dose in healthy subjects. Each healthy subject (N = 10) received rofecoxib (75 mg once daily) or placebo for 11 days in a double-blind, randomized, balanced, two-period crossover study. A single 0.5 mg oral dose of digoxin elixir was administered on the 7th day of each 11-day period. Each treatment period was separated by 14 to 21 days… CONTINUE READING